{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:38:25Z","timestamp":1786977505909,"version":"build-2736575974"},"reference-count":43,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer cachexia is characterized by weight loss and is associated with increased morbidity and mortality in patients with cancer. Anamorelin (ONO\u20107643; ANAM) is a novel and selective ghrelin receptor agonist that improves appetite, lean body mass (LBM), body weight, and anorexia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, open\u2010label, single\u2010arm study investigated the efficacy and safety of 100\u00a0mg anamorelin in 50 Japanese patients with advanced and unresectable gastrointestinal (colorectal, gastric, or pancreatic) cancer. ANAM was administered once daily over 12\u00a0weeks. The primary endpoint was the proportion of patients that maintained or gained LBM over the course of the study. Secondary endpoints included changes in LBM, body weight, quality of life (QoL), and nutritional status biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proportion of patients who responded to treatment was 63.3% (95% CI, 48.3%\u201076.6%), with a least square mean\u00a0\u00b1\u00a0SE change in LBM and body weight from baseline of 1.89\u00a0\u00b1\u00a00.36\u00a0kg and 1.41\u00a0\u00b1\u00a00.61\u00a0kg, respectively. Appetite\u2010related questions on the QoL questionnaire showed that ANAM improved appetite. Adverse events occurred in 79.6% of patients, and the most common treatment\u2010related adverse events were increased \u03b3\u2010glutamyl transpeptidase (8.2%), diabetes mellitus (6.1%), hyperglycemia (6.1%), and prolonged QRS complex (6.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ANAM improved anorexia and patients' nutritional status, resulting in rapid increases in LBM and body weight in patients with advanced gastrointestinal cancer who had cancer cachexia. ANAM treatment was well tolerated over 12\u00a0weeks. ANAM is a potential clinically beneficial pharmacotherapeutic option for patients with advanced gastrointestinal cancer who have cancer cachexia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.32406","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T16:02:18Z","timestamp":1565884938000},"page":"4294-4302","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["A multicenter, open\u2010label, single\u2010arm study of anamorelin (ONO\u20107643) in advanced gastrointestinal cancer patients with cancer cachexia"],"prefix":"10.1002","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9857-2095","authenticated-orcid":false,"given":"Satoshi","family":"Hamauchi","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology Shizuoka Cancer Center Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine Kyorin University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Toranomon Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Munemoto","sequence":"additional","affiliation":[{"name":"Department of Surgery Fukui\u2010ken Saiseikai Hospital Fukui Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Furuya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Japan Community Health Care Organization, Hokkaido Hospital Hokkaido Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Nagaoka Red Cross Hospital Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Choda","sequence":"additional","affiliation":[{"name":"Department of Surgery Hiroshima Citizens Hospital Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Higashiguchi","sequence":"additional","affiliation":[{"name":"Department of Surgery and Palliative Medicine Fujita Health University School of Medicine Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4047-2929","authenticated-orcid":false,"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Aichi Cancer Center Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine Kyoto Prefectural University of Medicine Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Oyama","sequence":"additional","affiliation":[{"name":"Data Science Ono Pharmaceutical Company Ltd Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6118-2977","authenticated-orcid":false,"given":"Toru","family":"Takiguchi","sequence":"additional","affiliation":[{"name":"Clinical Development Planning Ono Pharmaceutical Company Ltd Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Komura","sequence":"additional","affiliation":[{"name":"Clinical Development Planning Ono Pharmaceutical Company Ltd Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[{"name":"General Medical Research Center Fukuoka University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13539-014-0164-8"},{"key":"e_1_2_8_3_1","volume-title":"Clinical Practice Guidelines on Cancer Cachexia in Advanced Cancer Patients With a Focus on Refractory Cachexia","author":"Radbruch L","year":"2010"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0772-6"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2014.09.007"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(05)80001-3"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7117.1219"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3156-8"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.8010"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.07.015"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12117"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.152"},{"key":"e_1_2_8_13_1","first-page":"CD004310","article-title":"Megestrol acetate for treatment of anorexia\u2010cachexia syndrome","volume":"3","author":"Ruiz Garcia V","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30006-2"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00012.2004"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2011.06.029"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/518909"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-594"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.02.012"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.727390"},{"key":"e_1_2_8_21_1","first-page":"593","article-title":"Biological activity of RC\u20101291, a novel oral ghrelin mimetic for cancer anorexia\/cachexia: results from a phase I randomized, double\u2010blind, placebo\u2010controlled trial in healthy volunteers [abstract]","volume":"14","author":"Kumor K","year":"2006","journal-title":"Support Care Cancer"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1500-1"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71154-4"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00558-6"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.9500"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3144-z"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31128"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2008.06.013"},{"key":"e_1_2_8_29_1","unstructured":"National Institutes of Health National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. 2009. Available at:https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html. Accessed October 3 2018."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2010.07.015"},{"key":"e_1_2_8_31_1","first-page":"MC13","article-title":"Ghrelin: ghrelin as a regulatory peptide in growth hormone secretion","volume":"8","author":"Khatib N","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1800-0"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0027"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.153"},{"key":"e_1_2_8_35_1","first-page":"611","article-title":"Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice","volume":"123","author":"Porporato PE","year":"2013","journal-title":"J Clin Invest"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12023"},{"key":"e_1_2_8_37_1","first-page":"5","article-title":"Anamorelin HCl for the treatment of anorexia\u2010cachexia in lung cancer: study design and baseline characteristics of patients in the phase III clinical trial ROMANA 2 (HT\u2010ANAM\u2010302). Abstracts of the 7th Cachexia Conference, Kobe\/Osaka, Japan, December 9\u201011, 2013 [abstract]","volume":"4","author":"Abernethy A","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70055-X"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/db05-1183"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-13-74"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12351"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12201"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0183"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000381"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32406","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.32406","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:13:55Z","timestamp":1760296435000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.32406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":43,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/cncr.32406"],"URL":"https:\/\/doi.org\/10.1002\/cncr.32406","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,15]]},"assertion":[{"value":"2018-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}